Cargando…

Adjuvant Therapy in Adrenocortical Carcinoma: Reflections and Future Directions

Adrenocortical carcinoma (ACC) is a rare and aggressive malignancy with high risk of recurrence despite macroscopically complete surgical resection. The main predictors of ACC recurrence include advanced disease stage, incomplete surgical resection, cortisol production, certain genetic alterations,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bedrose, Sara, Daher, Marilyne, Altameemi, Lina, Habra, Mouhammed Amir
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7072549/ https://www.ncbi.nlm.nih.gov/pubmed/32098326 http://dx.doi.org/10.3390/cancers12020508

Ejemplares similares

SAT-175 Trial in Progress Interim Report: A Phase II Clinical Trial Using Single Agent Cabozantinib in Advanced Adrenocortical Carcinoma
por: Bedrose, Sara Shokry Daniel, et al.
Publicado: (2020)

Adjuvant therapy in adrenocortical carcinoma: prognostic factors and treatment options
por: Al-Ward, Ruaa, et al.
Publicado: (2022)

Adjuvant platinum-based chemotherapy in radically resected adrenocortical carcinoma: a cohort study
por: Kimpel, Otilia, et al.
Publicado: (2021)

Combined lenvatinib and pembrolizumab as salvage therapy in advanced adrenal cortical carcinoma
por: Bedrose, Sara, et al.
Publicado: (2020)

The Immunotherapy Landscape in Adrenocortical Cancer
por: Pegna, Guillaume J., et al.
Publicado: (2021)

Endocrine and Neuroendocrine Tumors Special Issue—Checkpoint Inhibitors for Adrenocortical Carcinoma and Metastatic Pheochromocytoma and Paraganglioma: Do They Work?
por: Jimenez, Camilo, et al.
Publicado: (2022)

SUN-348 Cabozantinib in Advanced Adrenocortical Carcinoma: Rationale and Protocol of Two Phase II Clinical Trials
por: Kroiss, Matthias, et al.
Publicado: (2019)

Response to Letter to the Editor From Berruti et al: “Cytoreductive Surgery of the Primary Tumor in Metastatic Adrenocortical Carcinoma: Impact on Patients’ Survival”
por: Srougi, Victor, et al.
Publicado: (2022)

Multikinase inhibitors use in differentiated thyroid carcinoma
por: Jasim, Sina, et al.
Publicado: (2014)

The prevalence and spectrum of reported incidental adrenal abnormalities in abdominal computed tomography of cancer patients: The experience of a comprehensive cancer center
por: Qdaisat, Aiham, et al.
Publicado: (2022)

RF19 | PSUN33 Adrenocortical Carcinoma as a Rare Manifestation of Birt-Hogg-Dubé Syndrome
por: Else, Tobias, et al.
Publicado: (2022)

PSAT010 Severe Cholestatic Jaundice (Stauffer Syndrome) as a Rare Paraneoplastic Manifestation in Adrenocortical Carcinoma
por: Murvelashvili, Natia, et al.
Publicado: (2022)

Relacorilant With Pembrolizumab: A Phase 1b, Open-Label Study of a Selective Glucocorticoid Receptor Modulator Combined With a Checkpoint Inhibitor for Patients With Adrenocortical Carcinoma With Excess Glucocorticoid Production
por: Habra, Mouhammed Amir, et al.
Publicado: (2021)

Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma
por: Habra, Mouhammed Amir, et al.
Publicado: (2019)

Past, Present and Future of Epigenetics in Adrenocortical Carcinoma
por: Ettaieb, Madeleine, et al.
Publicado: (2020)

FRI191 Changes In The Incidence And Geographical Distribution Of Adrenocortical Carcinoma: A Retrospective Analysis Of A State Cancer Registry
por: Brondani, Vania B, et al.
Publicado: (2023)

What Is the Optimal Duration of Adjuvant Mitotane Therapy in Adrenocortical Carcinoma? An Unanswered Question
por: Basile, Vittoria, et al.
Publicado: (2021)

Recovery of Adrenal Insufficiency Is Frequent After Adjuvant Mitotane Therapy in Patients with Adrenocortical Carcinoma
por: Poirier, Jonathan, et al.
Publicado: (2020)

Adjuvant Therapy for High-Risk Localized Renal Cell Carcinoma: Current Landscape and Future Direction
por: Buller, Dylan M, et al.
Publicado: (2023)

Adrenocortical carcinoma: current state of the art, ongoing controversies, and future directions in diagnosis and treatment
por: Shariq, Omair A., et al.
Publicado: (2021)

Adrenocortical Carcinoma: Current Therapeutic State-of-the-Art
por: Lebastchi, Amir H., et al.
Publicado: (2012)

Adjuvant radiotherapy for the primary treatment of adrenocortical carcinoma: are we offering the best?
por: Srougi, Victor, et al.
Publicado: (2017)

Benefits of Adjuvant Mitotane after Resection of Adrenocortical Carcinoma: A Systematic Review and Meta-Analysis
por: Tang, Yongquan, et al.
Publicado: (2018)

The Role of Biomarkers in Adrenocortical Carcinoma: A Review of Current Evidence and Future Perspectives
por: Mizdrak, Maja, et al.
Publicado: (2021)

Future Directions in Diagnosis, Prognosis and Disease Monitoring of Adrenocortical Carcinoma: Novel Non-Invasive Biomarkers
por: Cheng, Yuling, et al.
Publicado: (2022)

Medical Approaches in Adrenocortical Carcinoma
por: Paragliola, Rosa Maria, et al.
Publicado: (2020)

Apoptosis regulation in adrenocortical carcinoma
por: Pereira, Sofia S, et al.
Publicado: (2019)

Mitotane Concentrations Influence the Risk of Recurrence in Adrenocortical Carcinoma Patients on Adjuvant Treatment
por: Puglisi, Soraya, et al.
Publicado: (2019)

Current Status and Future Targeted Therapy in Adrenocortical Cancer
por: Alyateem, George, et al.
Publicado: (2021)

Adrenocortical Carcinoma
por: Berruti, Alfredo, et al.
Publicado: (2021)

Laparoscopic Adrenalectomy for Large Adrenocortical Carcinoma
por: Machado, Norman Oneil, et al.
Publicado: (2015)

The challenge of developmental therapeutics for adrenocortical carcinoma
por: Costa, Ricardo, et al.
Publicado: (2016)

The Role of Immunotherapy in the Treatment of Adrenocortical Carcinoma
por: Karwacka, Izabela, et al.
Publicado: (2021)

Adrenocortical Carcinoma in an Adult: Eight Months without Recurrence after Resection and Adjuvant Chemotherapy
por: Siosaki, Marcos Duarte, et al.
Publicado: (2014)

Results of the ADIUVO Study, the First Randomized Trial on Adjuvant Mitotane in Adrenocortical Carcinoma Patients
por: Terzolo, Massimo, et al.
Publicado: (2021)

Sex-Based Evaluation of Lipid Profile in Postoperative Adjuvant Mitotane Treatment for Adrenocortical Carcinoma
por: Allegra, Sarah, et al.
Publicado: (2022)

Loco-Regional Therapies in Oligometastatic Adrenocortical Carcinoma
por: Roux, Charles, et al.
Publicado: (2022)

The Potential of Steroid Profiling by Mass Spectrometry in the Management of Adrenocortical Carcinoma
por: Rossi, Claudia, et al.
Publicado: (2020)

Adrenocortical carcinoma: a literature review
por: Thampi, Ammu, et al.
Publicado: (2020)

Case Report: Adjuvant Therapy with a High Dose of Mitotane for Adrenocortical Carcinoma in a 4-year-old Boy
por: Goto, Takako, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_65485l8kkqj0si22ketcp59gnn